Literature DB >> 7947368

Effects of celiprolol vs. nifedipine on serum lipoproteins in patients with mild to moderate hypertension.

P Lijnen1, R Van Hoof, A Amery.   

Abstract

During a double-blind, randomized study in hypertensive patients, changes in plasma lipid and lipoprotein levels during treatment with celiprolol were compared with those occurring during nifedipine treatment. Fifty-three patients (28 men and 25 women) with mild-to-moderate hypertension, aged 20-64 years, were studied. After a 1-month placebo run-in period, patients were randomly assigned to receive either nifedipine (40 mg daily) or celiprolol (200 mg daily), each time using a double-dummy technique. After 6 weeks, dosages of each drug could be doubled. After 6 weeks, there were no differences in plasma lipids between the two treatment groups. However, the changes after 12 weeks of treatment were different (p < 0.05) between the groups, leading to lower levels of plasma esterified cholesterol, low-density lipoprotein (LDL) cholesterol, and apoprotein AI, AII, and B in the celiprolol group. Plasma lecithin cholesterol acyltransferase activity (LCAT) was not modified. The present study showed that celiprolol was at least equivalent to nifedipine in terms of secondary effects on plasma lipids and lipoprotein.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947368     DOI: 10.1007/bf00877929

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  15 in total

1.  Biochemical mechanisms involved in the beta-blocker-induced changes in serum lipoproteins.

Authors:  P Lijnen
Journal:  Am Heart J       Date:  1992-08       Impact factor: 4.749

2.  A long-term study of the effects of celiprolol on blood pressure and lipid-associated risk factors.

Authors:  J M Herrmann; E O Mayer
Journal:  Am Heart J       Date:  1988-11       Impact factor: 4.749

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

Review 4.  Pathogenesis and management of lipoprotein disorders.

Authors:  E J Schaefer; R I Levy
Journal:  N Engl J Med       Date:  1985-05-16       Impact factor: 91.245

Review 5.  Influence of multiple risk factors on the hazard of hypertension.

Authors:  W B Kannel
Journal:  J Cardiovasc Pharmacol       Date:  1990       Impact factor: 3.105

Review 6.  Beta-receptor blockade, physical activity, and metabolism.

Authors:  F W Lohmann; W A Loesment; H Kaehler
Journal:  J Cardiovasc Pharmacol       Date:  1990       Impact factor: 3.105

Review 7.  Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.

Authors:  R J Milne; M M Buckley
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

8.  Lipid effects of celiprolol, a new cardioselective beta-blocker, versus propranolol.

Authors:  C R Sirtori; B Johnson; V Vaccarino; G Montanari; M Cremoncini; G Gianfranceschi; M Sirtori; C A Dujovne
Journal:  Clin Pharmacol Ther       Date:  1989-06       Impact factor: 6.875

9.  Cholesterol determination in high-density lipoproteins separated by three different methods.

Authors:  M F Lopes-Virella; P Stone; S Ellis; J A Colwell
Journal:  Clin Chem       Date:  1977-05       Impact factor: 8.327

10.  Lecithin: cholesterol acyltransferase activity in familial hypercholesterolemia treated with simvastatin and simvastatin plus low-dose colestipol.

Authors:  J P Desager; Y Horsmans; C Harvengt
Journal:  J Clin Pharmacol       Date:  1991-06       Impact factor: 3.126

View more
  1 in total

Review 1.  Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.

Authors:  C J Dunn; C M Spencer
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.